[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX361499B - Baricitinib deuterado. - Google Patents

Baricitinib deuterado.

Info

Publication number
MX361499B
MX361499B MX2015002040A MX2015002040A MX361499B MX 361499 B MX361499 B MX 361499B MX 2015002040 A MX2015002040 A MX 2015002040A MX 2015002040 A MX2015002040 A MX 2015002040A MX 361499 B MX361499 B MX 361499B
Authority
MX
Mexico
Prior art keywords
baricitinib
deuterated
formula
compound
pharmaceutically acceptable
Prior art date
Application number
MX2015002040A
Other languages
English (en)
Other versions
MX2015002040A (es
Inventor
Roger D Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2015002040A publication Critical patent/MX2015002040A/es
Publication of MX361499B publication Critical patent/MX361499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención, en una modalidad, proporciona un compuesto de la Fórmula I: (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en donde las variables mostradas en la Fórmula I son como se define en la especificación.
MX2015002040A 2012-08-17 2013-08-15 Baricitinib deuterado. MX361499B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684196P 2012-08-17 2012-08-17
US201361780661P 2013-03-13 2013-03-13
PCT/US2013/055170 WO2014028756A1 (en) 2012-08-17 2013-08-15 Deuterated baricitinib

Publications (2)

Publication Number Publication Date
MX2015002040A MX2015002040A (es) 2015-06-05
MX361499B true MX361499B (es) 2018-12-06

Family

ID=49034261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002040A MX361499B (es) 2012-08-17 2013-08-15 Baricitinib deuterado.

Country Status (10)

Country Link
US (3) US9540367B2 (es)
EP (2) EP2885303B1 (es)
AU (1) AU2013302519B2 (es)
BR (1) BR112015003153A2 (es)
CA (1) CA2880083A1 (es)
EA (1) EA031716B1 (es)
ES (1) ES2717279T3 (es)
IN (1) IN2015DN01102A (es)
MX (1) MX361499B (es)
WO (1) WO2014028756A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013302519B2 (en) 2012-08-17 2017-11-02 Concert Pharmaceuticals, Inc. Deuterated baricitinib
EP3136857A4 (en) 2014-05-01 2017-09-20 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
ES2900184T3 (es) 2014-08-11 2022-03-16 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
EP3179992B1 (en) 2014-08-11 2022-05-11 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016125080A2 (en) * 2015-02-02 2016-08-11 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
RU2603959C1 (ru) * 2015-11-13 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
EP3713545A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Therapeutic compound formulations
WO2019104214A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Membrane emulsification device for microsphere creation
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
JP7565798B2 (ja) 2018-03-30 2024-10-11 インサイト・コーポレイション 炎症性皮膚疾患のバイオマーカー
SI3773593T1 (sl) 2018-03-30 2024-08-30 Incyte Corporation Zdravljenje hidradenitisa suppurative z zaviralci jak
WO2019200030A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
EP3941474A2 (en) 2019-03-19 2022-01-26 Incyte Corporation Biomarkers for vitiligo
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP7518900B2 (ja) 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
CA3204186A1 (en) 2020-12-04 2022-06-09 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases
AU2022206313A1 (en) 2021-01-11 2023-08-31 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
WO2024241078A1 (en) * 2023-05-22 2024-11-28 Eli Lilly And Company Treatment or prevention of new-onset type 1 diabetes with baricitinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
GEP20053466B (en) 2001-05-03 2005-02-25 Hoffmann La Roche Pharmaceutical Dosage Form of Amorphous Nelfinavir Mesylate, Method for its Production and Use
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN101076319A (zh) 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
JP2009511481A (ja) 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
EP2059241A1 (en) 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US7718754B2 (en) 2007-07-30 2010-05-18 Kao Corporation Promoter for polycondensation reaction
KR20120108042A (ko) * 2008-03-11 2012-10-04 인사이트 코포레이션 Ｊａｋ 억제제로서의 아제티딘 및 시클로부탄 유도체
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US8324200B2 (en) * 2009-01-23 2012-12-04 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2012079075A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
AU2013302519B2 (en) 2012-08-17 2017-11-02 Concert Pharmaceuticals, Inc. Deuterated baricitinib

Also Published As

Publication number Publication date
ES2717279T3 (es) 2019-06-20
WO2014028756A1 (en) 2014-02-20
AU2013302519A1 (en) 2015-02-12
US10842792B2 (en) 2020-11-24
AU2013302519B2 (en) 2017-11-02
US20150218158A1 (en) 2015-08-06
IN2015DN01102A (es) 2015-06-26
EP2885303A1 (en) 2015-06-24
US20170189406A1 (en) 2017-07-06
EA031716B1 (ru) 2019-02-28
CA2880083A1 (en) 2014-02-20
EA201590321A1 (ru) 2015-06-30
MX2015002040A (es) 2015-06-05
EP3492472A1 (en) 2019-06-05
EP2885303B1 (en) 2018-12-26
US9931343B2 (en) 2018-04-03
BR112015003153A2 (pt) 2017-07-04
US9540367B2 (en) 2017-01-10
US20180221374A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2015002040A (es) Baricitinib deuterado.
MX2015001246A (es) Ibrutinib deuterado.
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
IN2015DN00960A (es)
MY182082A (en) Biheteroaryl compounds and uses thereof
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
PH12015500900A1 (en) A stabilized pemetrexed formulation
IN2012DE00621A (es)
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MX2015008829A (es) Momelotinib deuterado.
IN2012DE00620A (es)
IN2014DN07996A (es)
HK1222848A1 (zh) 用作alk抑制劑的吡咯並三嗪
PH12015501146A1 (en) Hydantoin derivative
IN2014DN10669A (es)
GB201020397D0 (en) Compounds
MX2015012610A (es) Pacritinib deuterizado.
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями
UA87695U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид, що має інотропну активність
IN2013CH05395A (es)
UA89447U (ru) Соединение 1,1-диэтилкарбокси-2-хлор-2-трифторметилэтилен с потенциальными физиологическими свойствами
UA87254U (ru) Соединение 1,1-диэтилкарбокси-2-метокси-2-трифторметилэтилен с потенциальными физиологическими свойствами

Legal Events

Date Code Title Description
FG Grant or registration